The government is likely to peg fertiliser subsidy for next financial year at Rs 66,000 crore, lower than the actual outgo in 2011-12. "A moderate increase is likely," said a government official. The actual subsidy bill for the fiscal is likely to come at over Rs 70,000 crore though the government had budgeted for just Rs 49,997 crore in the budget 2011-12. Private analysts had soon after the presentation of the last...
More »SEARCH RESULT
India trades up, finds census by Asit Ranjan Mishra & Shuchi Bansal
The latest round of data on the 2011 Census shows that the country is exhibiting distinct signs of trading up as material living conditions improve for large sections of the population. Although this aggregate picture is not uniform across the country, analysts believe that the upward material mobility in society is creating the basis of a new consumer boom in the economy—serving up a perfect backdrop ahead of the presentation of...
More »White paper on black money likely in Budget Session: Govt
-PTI The Government today said it is likely to table a White Paper on black money during the ongoing Budget Session of Parliament, but maintained that there is no authentic estimate of the quantum of illicit wealth. "The white paper is likely to be brought during the Budget Session," Minister of State for Finance S S Palanimanickam informed the Rajya Sabha in a written reply. The White Paper is expected to contain information...
More »Government may be forced to keep its reform bills in cold storage
-The Economic Times The government may be forced to trim its legislative agenda - including pushing through long-pending bills on pensions, insurance and banking - following Congress' debacle in Uttar Pradesh and Punjab assembly elections. Pension, insurance and banking sector reforms are part of the legislative agenda of the UPA government but BJP leaders told finance minister Pranab Mukherjee at an outreach session that the government should first set its House in...
More »India's patent ruling on cancer may open door for cheaper HIV drugs
-Reuters India's move to strip German drugmaker Bayer of its exclusive rights to a cancer drug has set a precedent that could extend to other treatments, including modern HIV/AIDS drugs, in a major blow to global pharmaceutical firms, experts say. On Monday, the Indian Patent Office effectively ended Bayer's monopoly for its Nexavar drug and issued its first-ever compulsory license allowing local generic maker Natco Pharma to make and sell the drug...
More »